Uterine ultrasound and endometrial biopsy in tamoxifen users

References Jeon J, Kim SE, Lee DY et al (2020) Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies. Breast Cancer Res Treat 179:125–130 Fisher B, Costantino JP, Redmond CK et al (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527–537 Neven P, De Muylder X, Van Belle Y et al (1989) Tamoxifen and the uterus and endometrium. Lancet 8634:375 Dal Cin P, Timmerman D, Van den Berghe I et al (1998) Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen. Cancer Res 58:2278–2281 Neven P, Vergote I (1988) Should tamoxifen users be screened for endometrial lesions? Lancet 351:155–157 Author information Authors and Affiliations Corresponding author Ethics declarations Conflict of interest The authors declare that they have no conflict of interest. Ethical approval This article does not contain any studies with human participants performed by any of the authors. Additional information Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Rights and permissions About this article Cite this article Neven, P., Froyman, W., Timmerman, S. et al. Uterine ultrasound and endometrial biopsy in tamoxifen users. Breast Cancer Res Treat 180, 833–834 (2020). https://doi.org/10.1007/s10549-020-05595-5 Received: Accepted: Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s10549-020-05595-5